Jefferies Remains a Buy on DBV Technologies SA – American

By Austin Angelo

Jefferies analyst Biren Amin reiterated a Buy rating on DBV Technologies SA – American (NASDAQ: DBVT) today and set a price target of $47. The company’s shares closed yesterday at $33.20.

According to, Amin is a 3-star analyst with an average return of 2.7% and a 46.7% success rate. Amin covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Lion Biotechnologies Inc, and Bellicum Pharmaceuticals.

DBV Technologies SA – American has an analyst consensus of Moderate Buy, with a price target consensus of $47.

The company has a one year high of $37.98 and a one year low of $27.02. Currently, DBV Technologies SA – American has an average volume of 78.22K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. The company focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. It has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.